FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.
What happened
FDA reviewed RoenRx's website, roenrx.com, in March 2026 and found it offering compounded drug products including semaglutide. The pictured labels show "RoenRx" even though RoenRx is not the compounder, and site text states semaglutide is the active ingredient in FDA-approved Wegovy and Ozempic. FDA said this suggests the compounded products are FDA-approved when they are not.
What FDA found
The product labels shown on the website name RoenRx as if it made the drug, which it did not.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]Website claims linking the compounded semaglutide to FDA-approved Wegovy and Ozempic make it look FDA-approved when compounded drugs are not.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website's advertising for the compounded semaglutide is false or misleading, which misbrands the drug.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]Shipping misbranded drugs across state lines is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells RoenRx to send a written response to its compounding office within 15 business days, naming the entities that make the products, providing sample labeling, and correcting or removing the misleading website claims.
Who should pay attention
- telehealth platforms selling compounded semaglutide
- compounders whose products are resold under another brand's name
- marketing teams writing claims for compounded drug websites
This is a summary. Read the original letter on fda.gov.